Literature DB >> 11697801

Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro.

I Mathov1, L I Plotkin, C L Sgarlata, J Leoni, T Bellido.   

Abstract

Bisphosphonates (BPs) are analogues of pyrophosphate, which are widely used for the treatment of different pathologies associated with imbalances in bone turnover. Recent evidence suggested that cells of the osteoblastic lineage might be targets of the action of BPs. The objective of this work was to determine whether BPs induce proliferation of osteoblasts and whether this action involves activation of the extracellular signal-regulated kinases (ERKs). We have shown that three different BPs (olpadronate, pamidronate, and etidronate) induce proliferation in calvaria-derived osteoblasts and ROS 17/2.8 as measured by cell count and by [3H]thymidine uptake. Osteoblast proliferation induced by all BPs diminished to control levels in the presence of U0126, a specific inhibitor of the upstream kinase MEK 1 responsible for ERK phosphorylation. Consistent with this, BPs induced ERK activation as assessed by in-gel kinase assays. Phosphorylation of ERK1/2 was induced by the BPs olpadronate and pamidronate within 30 s, followed by rapid dephosphorylation, whereas etidronate induced phosphorylation of ERKs only after 90 s of incubation and returned to basal levels within 15-30 minutes. In addition, both BP-induced cell proliferation and ERK phosphorylation were reduced to basal levels in the presence of nifedipine, an L-type voltage-sensitive calcium channel (VSCC) inhibitor. These results show that BP-induced proliferation of osteoblastic cells is mediated by activation of ERKs and suggest that this effect requires influx of Ca2+ from the extracellular space through calcium channels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11697801     DOI: 10.1359/jbmr.2001.16.11.2050

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  18 in total

Review 1.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

Review 2.  Bisphosphonates: effects on osteoblast.

Authors:  Nicola Maruotti; Addolorata Corrado; Anna Neve; Francesco Paolo Cantatore
Journal:  Eur J Clin Pharmacol       Date:  2012-02-09       Impact factor: 2.953

3.  Osteoblastic cell secretome: a novel role for progranulin during risedronate treatment.

Authors:  Milena Romanello; Elzbieta Piatkowska; Giulia Antoniali; Laura Cesaratto; Carlo Vascotto; Renato V Iozzo; Daniela Delneri; Francesco L Brancia
Journal:  Bone       Date:  2013-10-11       Impact factor: 4.398

4.  TGF-β1 Regulation of P-JNK and L-Type Calcium Channel Cav1.2 in Cortical Neurons.

Authors:  Zhenning Liu; Jiangtao Sheng; Guoyi Peng; Jinhua Yang; Weiqiang Chen; Kangsheng Li
Journal:  J Mol Neurosci       Date:  2018-02-08       Impact factor: 3.444

5.  Bisphosphonates inhibit surface-mediated osteogenesis.

Authors:  Ethan M Lotz; Christoph H Lohmann; Barbara D Boyan; Zvi Schwartz
Journal:  J Biomed Mater Res A       Date:  2020-04-21       Impact factor: 4.396

6.  Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects.

Authors:  Addolorata Corrado; Francesco Paolo Cantatore; Maria Grano; Silvia Colucci
Journal:  Clin Rheumatol       Date:  2005-08-10       Impact factor: 2.980

7.  Role of connexin 43 in the mechanism of action of alendronate: dissociation of anti-apoptotic and proliferative signaling pathways.

Authors:  V Lezcano; T Bellido; L I Plotkin; R Boland; S Morelli
Journal:  Arch Biochem Biophys       Date:  2012-01-03       Impact factor: 4.013

8.  Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study.

Authors:  Hyung Keun Kim; Ji Hyun Kim; Azlina Amir Abbas; Taek Rim Yoon
Journal:  Clin Orthop Relat Res       Date:  2008-07-30       Impact factor: 4.176

9.  Osteogenic activity of locally applied small molecule drugs in a rat femur defect model.

Authors:  Jessica A Cottrell; Francis M Vales; Deborah Schachter; Scott Wadsworth; Rama Gundlapalli; Rasesh Kapadia; J Patrick O'Connor
Journal:  J Biomed Biotechnol       Date:  2010-06-16

Review 10.  Clodronic acid formulations available in Europe and their use in osteoporosis: a review.

Authors:  Bruno Frediani; Luca Cavalieri; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.